Exagen Inc. Plans to Release Quarterly Financial Results
Exagen Inc. (Nasdaq: XGN), a prominent player in autoimmune diagnostics, has announced that it will release its financial results for the second quarter of 2025. This anticipated announcement is scheduled for the morning of July 29, 2025, prior to market opening. The results are expected to reflect the company’s ongoing commitment to innovating in the field of autoimmune testing.
Conference Call Details
On the same day, John Aballi, the President and CEO of Exagen, alongside Chief Financial Officer Jeff Black, will lead a conference call at 8:30 a.m. ET. This call aims to provide insights into the company’s financial performance and the strategic measures being adopted to navigate the complexities of the market.
How to Participate in the Call
For those interested in participating, they can join by dialing 201-389-0918 for U.S. callers or +1-877-407-0890 for international participants. If you prefer a digital format, a link for the webcast will be available on the Exagen investor relations website, ensuring wider access for stakeholders.
Replay Information
A replay of the conference call will be accessible until August 12, 2025. Interested parties can listen to the recording by calling 201-612-7415 in the U.S. or +1-877-660-6853 internationally using the passcode 13753132. Furthermore, a recording of the webcast will also be available about an hour after the live call concludes, which allows for anyone who missed the initial conversation to catch up on the insights shared.
About Exagen Inc.
Exagen Inc., headquartered in San Diego County, California, is at the forefront of autoimmune diagnostics. Their commitment is to transform care for individuals battling chronic autoimmune conditions by providing clarity in decision-making and improving clinical outcomes through their extensive portfolio of innovative tests. One of their main products, AVISE® CTD, is instrumental in enabling healthcare providers to diagnose complex conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome accurately and efficiently.
Innovative Testing Solutions
The suite of AVISE-branded tests offered by Exagen supports healthcare professionals in diagnosing, predicting disease outcomes, and monitoring patient progress. This dedication to research and innovation positions Exagen as a leader in addressing the challenges faced in autoimmune disease management.
Commitment to Patient-Centered Care
Exagen’s focus remains on enhancing patient care through education, innovation, and comprehensive testing solutions. The company's approach aims not only to help patients but also to aid clinicians in making informed decisions, reflecting a dedication to the overall improvement of patient health and well-being.
Contact Information
For any inquiries related to Exagen's upcoming results or their diagnostic services, interested individuals can reach out to Ryan Douglas at Exagen Inc. via email at ir@exagen.com or call 760.560.1525 for assistance.
Frequently Asked Questions
When will Exagen Inc. announce its financial results?
Exagen Inc. plans to announce its financial results for the second quarter of 2025 on July 29, 2025, before the market opens.
Who will be presenting during the conference call?
The conference call will feature John Aballi, President and CEO, and Jeff Black, Chief Financial Officer of Exagen.
How can I access the conference call?
Participants can dial 201-389-0918 for U.S. callers or +1-877-407-0890 internationally to join the call.
Will there be a replay of the conference call?
Yes, a replay will be available until August 12, 2025. You can access it by calling 201-612-7415 in the U.S. using the passcode 13753132.
What is the mission of Exagen Inc.?
Exagen Inc. is committed to transforming care for patients with chronic autoimmune conditions through innovative testing and an emphasis on patient-centered strategies.
